CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor

Rygiel, Tomasz P.; Karnam, Guruswamy; Goverse, Gera; Marel, Arnold P. J. van der; Greuter, Mascha; Schaarenburg, Rosanne A. van; Visser, W. J.; Brenkman, Arjan B.; Molenaar, Rosalie; Hoek, Robert M.; Mebius, Reina E.; Meyaard, Linde

doi:10.1038/onc.2011.477

Cited by 69 publications

(56 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, challenging these mice, for instance by viral and bacterial infections, induced tumor formation and induced autoimmunity, leads to overt phenotypes. [20], [21], [24] CD200-CD200R axis also affects Toll-like receptor 2 and 4 responses, and thereby facilitates protection against excessive inflammatory responses [25], [26]. In the past, we have shown that Toll-like receptor 2 and 4 play a crucial role in arteriogenesis [27].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The CD200-CD200 Receptor Inhibitory Axis Controls Arteriogenesis and Local T Lymphocyte Influx

et al. 2014

View full text Add to dashboard Cite

The role of the CD200 ligand-CD200 receptor (CD200-CD200R) inhibitory axis is highly important in controlling myeloid cell function. Since the activation of myeloid cells is crucial in arteriogenesis, we hypothesized that disruption of the CD200-CD200R axis promotes arteriogenesis in a murine hindlimb ischemia model. Female Cd200−/− and wildtype (C57Bl/6J) mice underwent unilateral femoral artery ligation. Perfusion recovery was monitored over 7 days using Laser-Doppler analysis and was increased in Cd200−/− mice at day 3 and 7 after femoral artery ligation, compared to wildtype. Histology was performed on hindlimb muscles at baseline, day 3 and 7 to assess vessel geometry and number and inflammatory cell influx. Vessel geometry in non-ischemic muscles was larger, and vessel numbers in ischemic muscles were increased in Cd200−/− mice compared to wildtype. Furthermore, T lymphocyte influx was increased in Cd200−/− compared to wildtype. CD200R agonist treatment was performed in male C57Bl/6J mice to validate the role of the CD200-CD200R axis in arteriogenesis. CD200R agonist treatment after unilateral femoral artery ligation resulted in a significant decrease in vessel geometry, perfusion recovery and T lymphocyte influx at day 7 compared to isotype treatment. In this study, we show a causal role for the CD200-CD200R inhibitory axis in arteriogenesis in a murine hindlimb ischemia model. Lack of CD200R signaling is accompanied by increased T lymphocyte recruitment to the collateral vasculature and results in enlargement of preexisting collateral arteries.

show abstract

Section: Discussionmentioning

confidence: 99%

“…We previously showed that mice lacking CD200 suffer from increased immunopathology in response to influenza virus infections, compared to wildtype controls [20], for which T lymphocytes are essential. On the other hand, the absence of CD200-CD200R signaling breaks tumor tolerance and inhibits outgrowth of endogenous tumors [21].…”

Section: Introductionmentioning

confidence: 99%

The CD200-CD200 Receptor Inhibitory Axis Controls Arteriogenesis and Local T Lymphocyte Influx

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Also CD200R expression was shown on mouse and human mast cells, in these cells, CD200R engagement inhibited mast cell degranulation and decreased IL-13 and TNF secretions (Cherwinski et al, 2005). From the other point of view, CD200-CD200R signalling could benefit tumor cells and CD200 gene knockout mice were resistance to tumor induction; lymph nodes of these mice contained more regulatory T cells which tend to home tumours (Rygiel et al, 2012). Moreover, CD200 over-expression in transgenic mice could facilitate tumor cell metastasis while neutralising CD200 could result in decreased metastasis and increased antitumor cytotoxic lymphocytes (Gorczynski et al, 2011).…”

Section: Introductionmentioning

confidence: 95%

Structural properties of a viral orthologue of cellular CD200 protein: KSHV vOX2

et al. 2015

View full text Add to dashboard Cite

Kaposi׳s sarcoma-associated herpesvirus (KSHV) vOX2 is a cell surface glycoprotein expressed during viral lytic replication to suppress host inflammatory reactions. Here we have characterised vOX2 with biochemical, biophysical and bioinformatics tools and as a result propose a 3-dimensional model for vOX2 based on structural and functional homology with the PD-L1 protein. To validate this model, vOX2 was characterised by analytical ultracentrifugation (AUC) and circular dichroism spectroscopy (CD). The results identified the potential glycosylation sites and revealed that vOX2 is predominantly a beta-folded molecule with an RGD adhesion motif exposed on the C-terminal domain. The protein exists in monomer-dimer equilibrium similar to its IgV-type folded homologues, with 30-36% glycosylation and the molecular weight of the extracellular fragment of molecule is 32.0-33.6 kDa, much less than 50 kDa. Thus, the structural similarity to PD-L1 verifies its immunomodulatory potential and the RGD motif suggests an adhesive capacity.

show abstract

“…It has been demonstrated that lack of CD200R signaling inhibits outgrowth of endogenous tumours [34] (Rygiel et al, 2012). An interesting way to enhance the CD200-CD200R blockade is to combine the blocking agent with TLR7 stimulation.…”

Section: Dendritic Cells In Therapymentioning

confidence: 99%

Immune Cells As Targets and Tools For Cancer Therapy

Tonecka¹,

Pilch²,

Ramji³

et al. 2017

Immunotherapy

View full text Add to dashboard Cite

CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor

Cited by 69 publications

References 45 publications

The CD200-CD200 Receptor Inhibitory Axis Controls Arteriogenesis and Local T Lymphocyte Influx

The CD200-CD200 Receptor Inhibitory Axis Controls Arteriogenesis and Local T Lymphocyte Influx

Structural properties of a viral orthologue of cellular CD200 protein: KSHV vOX2

Immune Cells As Targets and Tools For Cancer Therapy

Contact Info

Product

Resources

About